The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: Results from the postmenopausal estrogen/progestin interventions mammographic density study

American Journal of Epidemiology

Volumn 162, Issue 9, 2005, Pages 826-834

  Greendale, Gail A ^a   Palla, Shana L ^b   Ursin, Giske ^c   Laughlin, Gail A ^d   Crandall, Carolyn ^a   Pike, Malcolm C ^c   Reboussin, Beth A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast neoplasms; Mammography; Menopause; Receptors; Risk factors; Steroid

Indexed keywords

BINDING PROTEIN; ESTRADIOL; ESTRONE; SEX HORMONE;

HEALTH AND DISEASE;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; DENSITY; FEMALE; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; PARITY; POSTMENOPAUSE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROMA CELL; TIME SERIES ANALYSIS;

BREAST; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; ESTRADIOL CONGENERS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; UNITED STATES;

EID: 27544485736     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwi286     Document Type: Article

References (53)

1. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987;9:146-74.
2. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208.
3. Warner E, Lockwood G, Math M, et al. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992;16:67-72.
4. Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
5. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003;12:332-8.
6. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst 1995;87:1622-9.
7. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94.
8. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126:1130-9.
9. American College of Radiology. Breast imaging reporting and data system: BI-RADS atlas. 4th ed. Reston, VA: American College of Radiology, 2003.
10. Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol 1987;148:1087-92.
11. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
12. Ursin G, Astrahan MA, Salane M, et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998;7:43-7.
13. Bright RA, Morrison AS, Brisson J, et al. Relationship between mammographic and histologic features of breast tissue in women with benign biopsies. Cancer 1988;61:266-71.
14. Urbanski S, Jensen HM, Cooke G, et al. The association of histological and radiological indicators of breast cancer risk. Br J Cancer 1988;58:474-9.
15. Bartow SA, Pathak DR, Mettler FA. Radiographic microcalcification and parenchymal pattern as indicators of histologic "high-risk" benign breast disease. Cancer 1990;66:1721-5.
16. Boyd NF, Jensen HM, Cooke G, et al. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-95.
17. Wellings SR, Wolfe JN. Correlative studies of the histological and radiographic appearance of the breast parenchyma. Radiology 1978;129:299-306.
18. Fisher ER, Palekar A, Kim WS, et al. The histopathology of mammographic patterns. Am J Clin Pathol 1978;69:421-6.
19. Moskowitz M, Gartside P, McLaughlin C. Mammographic patterns as markers for high-risk benign breast disease and incident cancers. Radiology 1980;134:293-5.
20. Arthur JE, Ellis IO, Flowers C, et al. The relationship of "high risk" mammographic patterns to histological risk factors for development of cancer in the human breast. Br J Radiol 1990;63:845-9.
21. Pike MC, Bernstein L, Spicer DV. Exogenous hormones and breast cancer risk. In: Niederhuber JE, ed. Current therapy in oncology. St. Louis, MO: BC Decker, Mosby-Year Book, Inc, 1993.
22. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
23. Söderqvist G. Effects of sex steroids on proliferation in normal mammary tissue. Ann Med 1998;30:511-24.
24. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53.
25. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
26. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
27. Espeland MA, Bush TL, Mebane-Sims I, et al. Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Control Clin Trials 1995;16(4 suppl): 3S-19S.
28. Colacurci N, Fomaro F, De Franciscis P, et al. Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril 2001;76:451-5.
29. Greendale GA, Bodin-Dunn L, Ingles S, et al. Leisure, home and occupational physical activity and cardiovascular risk factors in postmenopausal women: the postmenopausal estrogen/progestins intervention (PEPI) study. Arch Intern Med 1996;156:418-24.
30. Greendale GA, James MK, Espeland MA, et al. Can we measure postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. Am J Epidemiol 1997;146:763-70.
31. Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69.
32. Anderson DC, Hopper BR, Lasley BL, et al. A simple method for the assay of eight steroids in small volumes of plasma. Steroids 1976;28:179-96.
33. Tremblay RR, Dube JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 1974;10:599-605.
34. Rosner W. Isolation and characterization of the testosterone-estradiol- binding globulin from human plasma. Use of a novel affinity column. Biochemistry 1975;14:4813-20.
35. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9.
36. Byng JW, Boyd NF, Little L, et al. Symmetry of projection in the quantitative analyses of mammographic images. Eur J Cancer Prev 1996;5:319-27.
37. Belsley DA, Kuh E, Welsch RE. Regression diagnostics. New York, NY: John Wiley & Sons, 1980.
38. Stata Corporation. Stata statistical software, release 7.0. College Station, TX: Stata Corporation, 2001.
39. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographice densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.
40. Vachon CM, Kuni CC, Anderson K, et al. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000;11:653-62.
41. Chlebowski RT, McTiernan A. Biological significance of interventions that change breast density. (Editorial). J Natl Cancer Inst 2003;95:4-5.
42. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.
43. Byrne C, Colditz GA, Willett WC, et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
44. Trichopoulos D, MacMahon B, Cole P. The menopause and breast cancer. J Natl Cancer Inst 1972;48:605-13.
45. Tracy RE. Sex difference in coronary disease: two opposing views. J Chronic Dis 1966;19:822-33.
46. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
47. Fisher B, Powles TJ, Pritchard KJ. Tamoxifen for the prevention of breast cancer. Eur J Cancer 2000;36:142-50.
48. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-8.
49. Kahn SM, Hryb DJ, Nakhla AM, et al. Beyond carrier proteins: sex hormone-binding globulin is synthesized in target cells. J Endocrinol 2002;175:113-20.
50. Frairia R, Fortunati N, Berta L, et al. Sex steroid binding protein (SBP) receptors in estrogen sensitive tissues. J Steroid Biochem Mol Biol 1991;40:805-12.
51. Fortunati N, Fissore F, Fazzari A, et al. Sex steroid binding protein (SHBG) exerts a negative control on estradiol action in MCF-7 cells (human breast cancer) through cAMP and PKA. Effect on estradiol induced cell proliferation. Endocrinology 1996;137:686-92.
52. Nakhla AM, Rosner W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology 1996;137:4126-9.
53. Cauley JA, Gutai JP, Kuller LH, et al. Reliability and interrelations among sex hormones in postmenopausal women. Epidemiology 1991;133:50-7.